Bristol Myers Squibb CELG-RI
NYSE CELG-RI
$0.11 0.00 (-1.19%)
As of: Sep 10, 2026 · 11:55 AM EDT

Bristol Myers Squibb (CELG-RI) Construction in Progress (2015 - 2026)

Bristol Myers Squibb's (CELG-RI) quarterly Construction in Progress came in at $1.3 billion in Q2 2026, down 26.41% year-over-year from $1.8 billion in Q2 2025, and down 15.9% quarter-over-quarter from $1.5 billion in Q1 2026.

Analysis

Bristol Myers Squibb (CELG-RI) Construction in Progress (2015 - 2026) Analysis & Trends

Bristol Myers Squibb (CELG-RI) has reported Construction in Progress for 12 consecutive years, with $1.3 billion the latest figure, recorded in Q2 2026.

  • On a quarterly basis, Construction in Progress fell 26.41% year-over-year to $1.3 billion in Q2 2026; TTM through Jun 2026 was $1.3 billion, a 26.41% decrease from a year earlier, with the FY2025 full-year figure at $1.6 billion, up 6.16% from the prior year.
  • Construction in Progress was $1.3 billion for Q2 2026 at Bristol Myers Squibb, down from $1.5 billion in the prior quarter.
  • Over five years, Construction in Progress peaked at $1.8 billion in Q2 2025 and troughed at $800.0 million in Q1 2022.
  • A 5-year average of $1.3 billion and a median of $1.2 billion in 2024 frame the typical range for Construction in Progress.
  • Across the five-year window, Construction in Progress surged 54.14% in 2022 and dropped 26.41% in 2026, its largest moves.
  • Over 5 years, Construction in Progress stood at $1.1 billion in 2022, then climbed by 2.09% to $1.1 billion in 2023, then soared by 41.86% to $1.5 billion in 2024, then climbed by 6.16% to $1.6 billion in 2025, then dropped by 19.95% to $1.3 billion in 2026.
  • The last three Construction in Progress figures came in at $1.3 billion (Q2 2026), $1.5 billion (Q1 2026), and $1.6 billion (Q4 2025), per Business Quant data.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Construction in Progress (Qtr)
1 Johnson & Johnson 642.46 Bn 621.70 Bn 17.26 Bn -
2 AbbVie 447.01 Bn 440.44 Bn 12.70 Bn -
3 Merck 358.21 Bn 351.07 Bn 12.21 Bn -
4 Novartis Ag 267.54 Bn 259.85 Bn 11.24 Bn -
5 Pfizer 156.67 Bn 144.97 Bn 10.94 Bn -
6 Sanofi 52.23 Bn 44.85 Bn 10.79 Bn -
7 Revolution Medicines 42.86 Bn 42.86 Bn - -
8 Incyte 24.60 Bn 20.06 Bn 1.57 Bn -
9 United Therapeutics 21.31 Bn 18.64 Bn 683.80 Mn -
10 Bristol Myers Squibb 232.18 Mn -10.83 Bn 9.25 Bn 1.30 Bn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 1.30 Bn
Mar 31, 2026 1.54 Bn
Dec 31, 2025 1.62 Bn
Sep 30, 2025 1.46 Bn
Jun 30, 2025 1.76 Bn
Mar 31, 2025 1.66 Bn
Dec 31, 2024 1.53 Bn
Sep 30, 2024 1.37 Bn
Jun 30, 2024 1.26 Bn
Mar 31, 2024 1.21 Bn
Dec 31, 2023 1.08 Bn
Sep 30, 2023 1.11 Bn
Jun 30, 2023 1.20 Bn
Mar 31, 2023 1.07 Bn
Dec 31, 2022 1.05 Bn
Sep 30, 2022 973.00 Mn
Jun 30, 2022 850.00 Mn
Mar 31, 2022 800.00 Mn
Dec 31, 2021 764.00 Mn
Sep 30, 2021 695.00 Mn